AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy…
JEMPERLI is the first immuno-oncology treatment approved in the frontline setting for this patient population in…
Read More...
Read More...
Browsing Tag
Recurrent
New Treatment for Recurrent Ovarian Cancer Improves Survival
A study presented at…
Read More...
Read More...
Win for Vedolizumab in Recurrent Crohn’s Disease
CHICAGO -- Patients receiving vedolizumab (Entyvio)…
Read More...
Read More...
Sublingual Vaccine Shows Promise in Women With Recurrent UTIs
CHICAGO -- A sublingual vaccine not only reduced the risk…
Read More...
Read More...
Sobering OS Data With Maintenance Niraparib in Recurrent Ovarian Cancer
Niraparib (Zejula) maintenance did…
Read More...
Read More...
Low-Potassium Diet Not Enough to Stave off Recurrent Hyperkalemia
AUSTIN, Texas -- Dietary counseling alone wasn't cutting…
Read More...
Read More...
VTE Risk in Recurrent Ovarian Cancer Increases With More Lines of Chemotherapy
TAMPA, Fla. -- As lines of therapy increased for…
Read More...
Read More...
AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy…
<!-- Name:DistributionId Value:8796476 -->
<!--…
Read More...
Read More...